CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 159 enrolled / 159 target
Drug / intervention
PTC518 +1 moredrug
Likely dose
5 milligramsfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05358717
NCT05358717Phase 2CompletedMonitor (3.3/mo)Completion was 16mo ago
CompareCT.gov

A Phase 2A, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Efficacy of PTC518 in Subjects With Huntington's Disease

Novartis Pharmaceuticals·interventional·Posted May 3, 2022·Updated Jun 16, 2026

In Brief

A Phase 2 clinical trial evaluating PTC518 and Placebo for Huntington Disease. Completed, enrolled 159 participants across 28 sites in 11 countries.

Signals

Enrolling slower than its timeline implies

Detailed Summary

The primary goal of this study is to evaluate the safety and pharmacodynamic effects of PTC518 compared with placebo in participants with HD.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHuntington Disease
CountriesAustralia, Austria, Canada, France, Germany, Italy, Netherlands, New Zealand, Spain, United Kingdom, United States
Collaborators--

Timeline

Phase 2CompletedFinished
2023202420252026
First PostedMay 3, 2022
Enrollment StartJun 3, 2022
Primary CompletionFeb 7, 2025
Study CompletionJul 31, 2025
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 4.2 years ago

Arms & Interventions

PTC518 5 mgexperimental

Participants will receive PTC518 5 milligrams (mg) tablets once daily orally for 12 months.

Drug: PTC518
PTC518 10 mgexperimental

Participants will receive PTC518 10 mg tablets once daily orally for 12 months.

Drug: PTC518
PTC518 20 mgexperimental

Participants will receive PTC518 20 mg tablets once daily orally for 12 months.

Drug: PTC518
Placeboplacebo_comparator

Participants will receive placebo matching to PTC518 tablets once daily orally for 12 months.

Drug: Placebo

Interventions

PTC518drug

PTC518 will be administered per dose and schedule specified in the arm.

Placebodrug

Placebo matching to PTC518 will be administered per schedule specified in the arm.